Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation, Oncology, and Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ADORA3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen Delivery (Full-length GPCR Lentivirus) | ADORA3 Lentivirus Premade Particles; stable cell line generation; preserves native multipass transmembrane conformation; Sequence Verified. | View ADORA3 Products |
| Antigen (Soluble ECD) | ADORA3 N-Terminal ECD-Fc Fusion; high purity (>95%), endotoxin <1 EU/µg; HEK293 expressed with native glycosylation. | View ADORA3 Products |
| Gene Delivery | ADORA3 Promise-ORF; full-length ORF for custom expression; codon-optimized; Sequence Verified. | View ADORA3 Products |
| Benchmark Ab | Anti-ADORA3 Recombinant Antibody; high-purity positive control for Flow Cytometry and ICC; HEK293 expressed. | View ADORA3 Products |
| Validator | ADORA3 siRNA Set; for specific target knockdown verification. | View ADORA3 Products |
| Subfamily Control A | ADORA1; critical counter-screen for cardiovascular toxicity (bradycardia). | View ADORA1 Products |
| Subfamily Control B | ADORA2A; synergistic and selectivity profiling for immunomodulation. | View ADORA2A Products |
| Subfamily Control C | ADORA2B; hypoxia-driven TME pathway comparator. | View ADORA2B Products |
| Upstream Enzyme | CD73 (NT5E) Recombinant Protein; adenosine-generating enzyme; ECD-Fc fusion; purity >95%. | View NT5E Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformational Loss in Soluble Forms | Full-length ADORA3 Lentivirus for stable cell lines; preserves 7-TM topology and native glycosylation (HEK293 expression). |
| Subfamily Counter-Screening (A1 vs A2A vs A2B vs A3) | Comprehensive adenosine receptor family lentivirus panel available for strict selectivity assays. |
| Species Translation (Human to Mouse/Rat/Cyno) | Cross-species ORF clones (Human/Mouse/Rat/Cyno) for preclinical bridging studies. |
| Lack of Reliable Surface Expression Controls | Recombinant Anti-ADORA3 Antibodies specifically developed for Flow Cytometry validation. |
| False Positives in Functional Assays | Validated siRNA sets (including scrambled control) for precise background subtraction and specificity checks. |
| Gi/o-coupled Signal Detection | High-expression stable lines suitable for cAMP modulation screening. |
Live ADORA3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ADORA3 therapeutics is intensifying, with major players advancing from early exploratory stages to late-stage clinical trials. Historically dominated by small molecule agonists for inflammatory indications (e.g., Psoriasis, Rheumatoid Arthritis), the next wave of R&D is aggressively targeting oncology (Hepatocellular Carcinoma) and metabolic disorders (NASH). Due to ADORA3's complex role as a Gi/o-coupled G-protein coupled receptor, overcoming subfamily promiscuity remains the primary developmental hurdle. Future pipelines emphasize ultra-selective allosteric modulators, biased ligands (e.g., favoring β-arrestin over G-protein coupling), and targeted delivery mechanisms to isolate ADORA3's apoptotic and anti-inflammatory pathways without triggering A1 or A2A mediated systemic events. While ADORA2A antagonists dominate current immuno-oncology pipelines, ADORA3 offers distinct biology with potential for reduced cardiovascular liabilities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Can-Fite BioPharma, Topica Pharma | Psoriasis, HCC, NASH, Autoimmune Diseases | cAMP / Calcium Flux Assay (Need stable, high-expressing Lentivirus cell lines preserving native GPCR fold) |
| Small Molecule Antagonist | Emerging biotechs / academic programs | Solid Tumors (TME modulation), Asthma | Selectivity Panel vs ADORA1/ADORA2A/ADORA2B (Need matched paralog stable cell lines for competitive binding) |
| Allosteric Modulator (PAM) | Academic / Pharma consortia | Neuropathic Pain, Glaucoma, Chronic Pain | Conformational Biosensor Assay (Requires conformationally intact GPCR via lentiviral expression) |
| Biased Ligands | Structure-based design programs | Oncology, Cardioprotection | β-arrestin vs. G-protein Bias Quantification (Requires stable expression cell lines for pathway-specific assays) |